BiotechTube
Deep Breath Intelligence

Deep Breath Intelligence

Zurich, Switzerland· Est.
dbi.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Deep Breath Intelligence is a Zurich-based diagnostics company pioneering the field of breath metabolomics. Its core platform integrates proprietary breath collection hardware (BreathCollector, BreathInjector) with a sophisticated analytical backend using SESI-HRMS and AI/ML to identify disease biomarkers. The company operates a hybrid business model, selling research-use products and offering fee-for-service contract research, while developing its first software-as-a-medical-device, DBI-EPIbreath®, for therapeutic drug monitoring. Positioned at the intersection of non-invasive diagnostics and personalized medicine, DBI targets both the research market and future clinical applications.

Diagnostics

Technology Platform

Integrated breath metabolomics platform combining proprietary hardware for breath collection (BreathCollector, BreathInjector), SESI-HRMS (Secondary Electrospray Ionization - High-Resolution Mass Spectrometry) for analytical detection, and advanced AI/ML algorithms for data analysis and biomarker pattern recognition.

Opportunities

The global shift towards non-invasive, personalized diagnostics creates a massive opportunity for validated breath analysis.
DBI can capitalize on the growing therapeutic drug monitoring market with DBI-EPIbreath® and later expand into high-value areas like early cancer detection and infectious disease diagnosis, leveraging its integrated platform.

Risk Factors

Key risks include the clinical and technical validation of breath biomarkers, navigating complex regulatory pathways (especially EU IVDR), achieving clinical adoption and reimbursement for a novel diagnostic, and competition from other breath analysis firms and broader diagnostic technologies.
As a private company, it also faces funding risk.

Competitive Landscape

DBI competes in the emerging breath diagnostics space with companies like Owlstone Medical (UK) and Menssana Research (US), which also develop breath collection and analysis platforms. It also faces indirect competition from established diagnostic giants and liquid biopsy companies advancing non-invasive testing via blood. DBI's differentiation lies in its specific SESI-HRMS focus and integrated hardware/software/service model.

More companies in Diagnostics & Precision Medicine →More companies in Switzerland →